Novoste hopes to win the commercial race to develop radiation treatment for restenosis
This article was originally published in Clinica
For three decades radiation has been known to prevent restenosis. Companies have taken differing routes to achieve market leadership in a sector estimated to be worth between $500 million and $600 million in 2001. Analysts at Piper Jaffray say that Novoste has the most promise, but Johnson & Johnson could be the first on the US market.